Enliven Therapeutics Inc

Enliven Therapeutics Inc(ELVN)资讯与事件

$57.860

-0.029 (-0.05%)收盘时

ELVN 资讯

ELVN 事件

8/5 16:30

Enliven Cash and Securities Reach $895.2M, Preparing to Advance ELVN-001

As of June 30, 2026, the Company had cash, cash equivalents and marketable securities totaling $895.2M, which is expected to provide cash runway into 2030. "Q2 was an important period for Enliven as we announced compelling updated clinical data for ELVN-001, reached alignment with the FDA on key components of the ENABLE-2 Phase 3 2L+ trial design, and significantly strengthened our balance sheet," said CEO Rick Fair. "The updated Phase 1 data support ELVN-001's potential to become a best-in-class treatment for patients living with CML. Combined with our recent regulatory and financial progress, we are well positioned to initiate ENABLE-2 later this year and rapidly advance ELVN-001 across all lines of CML therapy."

6/12 12:30

Enliven Stock Rises 9.9% to $44.37

Enliven is up 9.9%, or $4.01 to $44.37.

6/12 07:30

Deal Size Increased to $400M

The deal size was increased to $400M in common stock from $250M in common stock. Jefferies, Goldman Sachs, Morgan Stanley and Barclays acted as joint book running managers for the offering.

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

免费开始